Longeveron(US:LGVN) Newsfilter·2024-05-28 12:05Core Insights - Longeveron Inc. is participating in the BIO International Convention from June 3-6, 2024, to explore partnership opportunities for its Alzheimer's disease program [1][2] - The company's lead investigational candidate, Lomecel-B™, has shown promising results in Phase 2a clinical trials, indicating its potential in treating mild Alzheimer's disease [3][4] Company Overview - Longeveron is a clinical stage biotechnology company focused on developing regenerative medicines to address unmet medical needs, with Lomecel-B™ being its primary product [5] - The company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty [5] Clinical Trial Results - In the completed Phase 2a clinical trial (CLEAR MIND), Lomecel-B™ demonstrated an overall slowing of disease progression in treated patients compared to placebo, achieving primary safety and secondary efficacy endpoints [3][4] - Statistically significant improvements were observed in pre-specified clinical and biomarker endpoints for specific groups receiving Lomecel-B™ [3] Upcoming Presentations - Full results from the CLEAR MIND study will be presented at the 2024 Alzheimer's Association International Conference (AAIC), highlighting the therapeutic potential of Lomecel-B™ [3]